Celltrion Inc.
Scope
Date
~
-
Bio & Pharma
Celltrion gets OK partial approval for phase 3 of biosimilar in Europe
South Korean biopharmaceutical company Celltrion Inc. announced on Tuesday that it has received approval from the European Medicines Agency (EMA) fo...
Aug 22, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to merge with global sales affiliate by end-2023
South Korean pharmaceutical giant Celltrion Group has begun procedures to merge biopharmaceuticals developer and producer Celltrion Inc. with global...
Aug 17, 2023 (Gmt+09:00)
-
Pre-IPOs
SK Pharmteco to raise $500 mn in pre-IPO, aims for 2025 listing
SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), is set to raise $500 millio...
Jul 18, 2023 (Gmt+09:00)
-
Carbon neutrality
Samsung Biologics, Celltrion pledge major CO2 cuts
South Korea’s No. 1 biopharmaceutical company Samsung BioLogics Co. and No. 2 Celltrion Inc. produced higher CO2 emissions last year than in 2...
Jul 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches Humira biosimilar Yuflyma in US
South Korean biopharmaceutical company Celltrion Healthcare on Monday said it launched the day before on the US market Yuflyma, a biosimilar of the ...
Jul 04, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in US for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...
Jun 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion puts Takeda’s assets up for sale after 3 years
South Korea’s Celltrion Inc. has put its Japanese Takeda Pharmaceutical Co.'s primary care assets acquired in 2020 on sale as the biosimilar g...
Jun 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US
South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA...
Jun 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand biosimilar portfolio to 11 by 2025
South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it plans to beef up its portfolio by applying for regulatory approv...
Jun 13, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to develop Humira biosimilar oral medication with US firm
South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...
Jun 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Remsima SC praised in Europe as preferred biosimilar
MILAN – South Korea's biopharmaceutical company Celltrion Inc. is known in Europe for its biosimilar products such as autoimmune disease treat...
Jun 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion unveils phase 1 clinical data of Actemra biosimilar in Europe
South Korean biosimilar giant Celltrion Inc. revealed on Wednesday the highly anticipated clinical phase 1 data for its Actemra biosimilar, CT-P47, ...
May 31, 2023 (Gmt+09:00)
-
Bio & Pharma
BIO USA 2023 to draw S.Korean biotech leaders, startups
More than 500 South Korean companies from top business groups to AI-based biotech startups are slated to attend the Bio International Convention 202...
May 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets FDA approval for Humira biosimilar CT-P17
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...
May 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches Remsima SC in Brazil
South Korean biopharmaceutical company Celltrion Healthcare Co. revealed on Monday its introduction of Remsima SC, a treatment for autoimmune diseas...
May 22, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion drops bid to acquire Baxter’s biopharm unit
Celltrion Inc. announced on Tuesday it has decided not to pursue the acquisition of the biopharmaceutical unit of U.S. medical device maker Baxter I...
May 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for Phase 3 clinical trials in Europe for biosimilar
South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...
May 03, 2023 (Gmt+09:00)
-
Energy
SK, KHNP partner with TerraPower for SMR development
SK Inc., SK Innovation Co. are partnering with Korea Hydro & Nuclear Power Co. (KHNP) and TerraPower, a US small modular reactor (SMR) des...
Apr 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey
South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...
Apr 21, 2023 (Gmt+09:00)
-
Private equity
MBK Partners co-founder tops 50 richest S.Koreans: Forbes
Michael ByungJu Kim, co-founder and partner at private equity firm MBK Partners, has topped the ranking of the 50 richest South Koreans by net worth...
Apr 18, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Celltrion Healthcare launches Vegzelma in US
South Korea's Celltrion Healthcare Co. on Monday said it launched on the US market Vegzelma, a biosimilar of Bevacizumab, a medication for colorecta...
Apr 17, 2023 (Gmt+09:00)
-
Shareholder activism
KCGI’s ascent to intensify family feud over DB control; DB stocks rally
A sibling feud over management control of DB Group is expected to intensify following the ascent of South Korean activist fund Korea Corporate Gover...
Apr 04, 2023 (Gmt+09:00)
-
Bio & Pharma
Biosimilar giant Celltrion to transform into drug developer
South Korean biosimilar giant Celltrion Group aims to transform into a drug developer by generating 40% of sales from new medicines by 2030 as it is...
Mar 29, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion founder returns to management with M&A pledge
South Korean biosimilar giant Celltrion Group’s founder Seo Jung-jin has returned to management two years after his departure, pledging to mer...
Mar 28, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion eyes Baxter's arm as it gears up for M&As
Celltrion Inc., South Korea’s largest biosimilar maker, said on Tuesday it has studied a possible acquisition of the biopharma solutions unit ...
Mar 21, 2023 (Gmt+09:00)
-
Supply chain
Samsung SDS acquires Korea’s No. 1 procurement SCM company
Samsung SDS Co., the information technology service unit of South Korea's Samsung Group, has acquired a 33.39% stake in Emro Inc., Korea's top suppl...
Mar 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Genuv sign agreement for antibody joint R&D
South Korean biopharmaceutical firm Celltrion Inc. announced on Tuesday a joint research and development agreement with Genuv, Inc., a domestic drug...
Mar 14, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion ex-Chairman Seo set to return to management; group stocks rally
South Korea’s biosimilar giant Celltrion Group’s founder and Honorary Chairman Seo Jung-jin is readying to return to management just two...
Mar 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion teams up with bio venture to develop new anti-cancer drug
South Korea's biopharmaceutical company Celltrion Inc. will develop an anti-cancer drug that combines oncolytic virus technology with biosimilars un...
Feb 28, 2023 (Gmt+09:00)
-
Bio & Pharma
Brazil approves Celltrion Pharm’s syringe facility
Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for it...
Feb 20, 2023 (Gmt+09:00)
Latest News
- 1 BMW Surpasses Mercedes for the First Time in 10 Years – Imported Car Market 'Shake-Up'
- 2 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 3 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 4 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 5 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google